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C ytomegalovirus (CMV) belongs to the herpes virus family and remains latent within the human 
body.  Symptomatic CMV disease rarely occurs in an 
immunocompetent host,  whereas immunosuppressed 
patients are susceptible to developing CMV infections.  
CMV affects various organs,  frequently causing retini-
tis,  pneumonitis,  gastroenteritis,  hepatitis,  and 
encephalitis.  Among CMV infections involving the 
gastrointestinal tract,  one of the most typical manifes-
tations is colorectal ulcers in ulcerative colitis patients 
[1].  Conversely,  the prevalence of upper gastrointesti-
nal tract lesions is relatively low [2],  and only a few 
articles have presented large series of patients with this 
disease [3-8].  In the present study,  we retrospectively 
analyzed the endoscopic features and clinical back-
ground of 14 patients with CMV-related lesions in the 
upper gastrointestinal tract.
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We retrospectively analyzed the cases of 14 patients (9 women,  5 men,  mean age: 51.6 years) with cytomegalo-
virus (CMV) involvement in the esophagus,  stomach,  and/or duodenum diagnosed at a single center,  to deter-
mine their endoscopic features and clinical backgrounds.  Thirteen patients (92.9%) had hematologic dis-
ease; the other had rheumatoid arthritis.  Of the former,  12 patients underwent allogeneic hematopoietic stem 
cell transplantation,  and 9 of these patients had graft-versus-host disease (GVHD) before undergoing esoph-
agogastroduodenoscopy (EGD).  All 14 patients had been taking one or more immunosuppressive agents 
including cyclosporine (n = 10),  corticosteroids (n = 9),  mycophenolic acid (n = 6),  tacrolimus (n = 3),  and 
methotrexate (n = 1).  Tests for CMV antigenemia were positive in 11 patients (78.6%).  EGD examinations 
revealed esophageal (n = 3),  gastric (n = 9),  and duodenal involvement (n = 6).  Macroscopically,  esophageal 
lesions by CMV infection presented as redness (n = 1),  erosions (n = 1),  and ulcers (n = 1).  Gastric lesions man-
ifested as redness (n = 7),  erosions (n = 3),  exfoliated mucosa (n = 2),  and verrucous erosions (n = 1).  Mucosal 
appearances in the duodenum varied: redness (n = 2),  ulcers (n = 2),  multiple erosions (n = 2),  single erosion 
(n = 1),  edema (n = 1).  CMV was detected even in the intact duodenal mucosa (n = 1).  In conclusion,  physi-
cians must recall the relevance of CMV infection when any mucosal alterations exist in the upper gastrointesti-
nal tract of immunosuppressed patients.
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Materials and Methods
A database search of medical records at the 
Department of Pathology at Okayama University 
Hospital identified 14 patients with CMV infection in 
the upper gastrointestinal tract (esophagus,  stomach,  
and duodenum) diagnosed between July 2003 and 
February 2015.  The diagnosis of CMV infection was 
made histologically,  based on the existence of intranu-
clear or cytoplasmic inclusion bodies and/or positive 
immunophenotypic staining for CMV on endoscopi-
cally biopsied specimens (Fig. 1).  The presence of graft-
versus-host disease (GVHD) was also histologically 
investigated in each biopsied sample.  We reviewed the 
patients’ clinical records to collect data on the patients’ 
background and the endoscopic,  radiologic,  biologic,  
and pathologic examinations performed.  One of the 14 
patients examined was also the subject in our case 
report [9].  The Ethical Committee of the Okayama 
University Hospital approved this study (no. 1041),  
which also adhered to the Declaration of Helsinki.
Results
We summarize the patients’ backgrounds in Table 1.  
The cases included 9 women and 5 men,  and their 
mean age was 51.6 years.  All but one patient (i.e.,  13 of 
the 14 patients) were diagnosed with a hematologic dis-
ease: acute myeloid leukemia (n = 6),  extranodal NK/T 
cell lymphoma,  nasal type (n = 2),  chronic active 
Epstein-Barr virus infection (n = 1),  aplastic anemia 
(n = 1),  follicular lymphoma (n = 1),  myelodysplastic 
syndrome (n = 1),  and chronic lymphocytic leukemia 
(n = 1).
Seven of these 13 patients underwent allogeneic 
bone marrow transplantation,  and 5 patients under-
went umbilical cord blood transplantation for the treat-
ment of hematologic diseases.  All 12 of these patients 
were on immunosuppressant medicine for the preven-
tion or treatment of GVHD.  One patient (Case 14) had 
been taking cyclosporine for the treatment of cytopenia 
associated with chronic lymphocytic leukemia (10).  The 
last patient was diagnosed with rheumatoid arthritis 
(Case 12) and was treated with methotrexate.
All 14 patients had been taking one or more immu-
nosuppressive agents including cyclosporine (n = 10),  
steroids (n = 9),  mycophenolic acid (n = 6),  tacrolimus 
(n = 3),  and methotrexate (n = 1).  None of the patients 
were infected with the human immunodeficiency virus 
(HIV).  Among the 12 patients who underwent alloge-
neic hematopoietic stem cell transplantation,  esoph-
agogastroduodenoscopy (EGD) was performed 29 to 
221 days after transplantation.  At the EGD examina-
tion,  9 patients had symptoms of acute GVHD,  which 
manifested as skin eruption and/or diarrhea in 7 
patients; the other 2 had symptoms of chronic GVHD,  
manifesting as skin eruption and elevated liver enzymes 
in 1 patient and histologically proven gastric GVHD in 
the other.
The chief complaints that prompted EGD examina-
tion were nausea (n = 6),  diarrhea (n = 3),  appetite loss 
(n = 3),  vomiting (n = 2),  throat irritation (n = 1),  
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Fig. 1　 Pathological images of CMV infection in the stomach (Case 3).  Intranuclear and cytoplasmic inclusion bodies are shown in 
hematoxylin and eosin staining (A,  arrows).  Immunophenotypic staining for CMV was also positive (B).
abdominal pain (n = 1),  epigastric pain (n = 1),  hemate-
mesis (n = 1),  precordial discomfort (n = 1),  swallowing 
pain (n = 1),  and fever (n = 1).  All patients were tested 
for CMV antigenemia before the procedure,  and the 
results were positive in 11 patients (78.6%) and negative 
in 3 patients.  It is noteworthy that among the 3 patients 
for whom the CMV antigenemia assay was negative,  the 
results turned out to be positive 4 days after EGD exam-
ination in 1 patient (Case 5) and 11 days after EGD 
examination in another (Case 2).
The EGD and biopsy examinations revealed the 
involvement of one or more sites.  The esophagus was 
involved in 3 patients; 9 patients had gastric involve-
ment and 6 had duodenal involvement (Table 2).  
Macroscopically,  esophageal lesions by CMV infection 
presented as redness (n = 1),  erosions (n = 1),  and 
ulcers (n = 1) (Fig. 2).  Gastric lesions were viewed as 
redness (n = 7),  erosions (n = 3),  exfoliated mucosa 
(n = 2),  and verrucous erosions (n = 1) (Fig. 3).  In the 
duodenum,  CMV involvement was detected in the 
mucosa by redness (n = 2),  ulcers (n = 2),  multiple ero-
sions (n = 2),  single erosion (n = 1),  edema (n = 1) 
(Fig. 4).  Moreover,  CMV involvement was detected 
even in intact duodenal mucosa.
In biopsied samples,  GVHD was histologically con-
firmed in 2 cases (Cases 2 and 5) and suspected in 2 
cases (Cases 7 and 8).  This was in addition to histologic 
evidence of CMV infection.  The endoscopic features of 
the 14 cases are summarized in Table 3.
Following the histologic diagnosis of CMV infection 
in the upper gastrointestinal tract or positive results of 
CMV antigenemia,  antiviral drugs were administered 
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Table 1　 Clinical background of the patients
No. Age Sex Underlying diseases Symptoms Immunosuppressive agents CMV antigenemia＊
1 19.4 F CAEBV,  post CBT (day 57) Throat irritation,  abdominal pain,  
diarrhea
Mycophenolic acid,  cyclosporine,  
steroid
Positive (25 cells/50,000 cells)
2 36.3 M Acute myeloid leukemia,  acute 
GVHD (skin),  post UR-BMT (day 43) Appetite loss,  diarrhea,  fever Cyclosporine,  steroid Negative
†
3 40.9 F Extranodal NK/T cell lymphoma,  
nasal type,  post UR-BMT (day 29) Vomiting,  epigastric pain Tacrolimus,  steroid Positive(4 cells/2 slides)
4 43.4 F Aplastic anemia,  chronic GVHD 
(gut),  post UR-BMT (day 221) Nausea,  appetite loss
Mycophenolic acid,  tacrolimus,  
steroid
Positive (7 cells/63,000 cells)
5 51.2 F Follicular lymphoma,  acute GVHD 
(skin),  post UR-BMT (day 34) Nausea Cyclosporine,  steroid Negative
‡
6 53.4 M Acute myeloid leukemia,  post CBT 
(day 48) Nausea,  vomiting Cyclosporine Positive (11 cells/56,000 cells)
7 55.8 F Acute myeloid leukemia,  acute 
GVHD (skin),  post CBT (day 31) Hematemesis
Mycophenolic acid,  cyclosporine,  
steroid
Positive (57 cells/28,000 cells)
8 55.9 M
Acute myeloid leukemia,  acute 
GVHD (skin,  gut),  post UR-BMT 
(day 47)
Nausea Tacrolimus,  steroid Positive (2 cells/29,000 cells)
9 56.2 M
Acute myeloid leukemia,  acute 
GVHD (skin,  gut),  post UR-BMT 
(day 35)
Diarrhea Cyclosporine,  steroid Positive (115 cells/70,000 cells)
10 57.6 M
Myelodysplastic syndrome,  chronic 
GVHD (skin,  liver),  post UR-BMT 
(day 153)
Appetite loss
Mycophenolic acid,  cyclosporine,  
steroid
Positive (7 cells/33,000 cells)
11 59.9 F
Extranodal NK/T cell lymphoma,  
nasal type,  acute GVHD (skin),  post 
CBT (day 77)
Nausea Mycophenolic acid,  cyclosporine Positive (13 cells/50,000 cells)
12 60.2 F Rheumatoid arthritis Nausea Methotrexate Positive (20 cells/50,000 cells)
13 61.3 F Acute myeloid leukemia,  acute 
GVHD (skin,  gut),  post CBT (day 29) Precordial discomfort Mycophenolic acid,  cyclosporine Positive (3 cells/52,000 cells)
14 70.9 F Chronic lymphocytic leukemia Pain on Swallowing Cyclosporine Negative
CAEBV,  chronic active Epstein-Barr virus infection; CBT,  umbilical cord blood stem cell transplantation; GVHD,  graft versus host disease; UR-BMT,  unrelated 
donor-bone marrow transplantation; CMV,  cytomegalovirus.
＊C7-HRP tests,  except for Case 3 where C10/C11 test was performed
†Turned to be positive (1 cell/25,000 cells) 11 days after esophagogastroduodenoscopy
‡Turned to be positive (1 cell/30,000 cells) 4 days after esophagogastroduodenoscopy
(i.e.,  ganciclovir,  foscarnet,  and valganciclovir).  The 
upper gastrointestinal tract was re-evaluated in 9 
patients.  CMV-related upper gastrointestinal lesions 
improved after antiviral treatment in 5 patients,  
improved partially in 2 patients,  and did not improve 
in 2 patients.
Discussion
Our retrospective analysis of the patients with CMV 
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Table 2　 Endoscopic features of the patients
No. Endoscopic features (location) GVHD by histology Outcome of CMV-related upper GI tract lesions
1 Redness (stomach),  redness (duodenum) Negative N/A
2 Redness (stomach) Positive Improved with ganciclovir treatment
3 Verrucous erosions (stomach) Negative Partially improved with ganciclovir treatment
4 Redness,  exfoliated mucosa (stomach) Negative Not improved with ganciclovir & foscarnet treatment
5 Ulcers (duodenum) Positive Improved with ganciclovir treatment
6 Redness,  erosions (stomach),  intact mucosa (duodenum) Negative Not improved with ganciclovir treatment
7 Erosions,  edema (duodenum) Suspected Improved with foscarnet treatment
8 Erosions,  ulcers (duodenum) Suspected Improved with ganciclovir treatment
9 Redness (esophagus),  redness,  erosions (stomach) Negative N/A
10 Erosions (esophagus),  exfoliated mucosa (stomach) Negative Partially improved with foscarnet treatment
11 Redness,  erosions (stomach) Negative N/A
12 Redness,  single erosion (duodenum) Negative N/A
13 Redness (stomach) Negative N/A
14 Ulcers (esophagus) Negative Improved with valganciclovir treatment
GVHD,  graft versus host disease; CMV,  cytomegalovirus; GI,  gastrointestinal; N/A,  not available since reevaluation by endoscopy examination was 
not performed.
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Fig. 2　 Endoscopic images of 
esophageal involvement with 
CMV.  Esophageal lesions by 
CMV infection are presented as 
redness (A,  arrow,  Case 9),  ero-
sions (B,  Case 10),  and ulcers 
(C,  D,  Case 14).
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Fig. 3　 Endoscopic images of 
CMV involvement in the stomach.  
Gastric lesions are shown as ver-
rucous erosions (A,  Case 3),  
exfoliated mucosa (B,  Case 10),  
and redness (C,  D,  Case 1),  in 
addition to erosions.  In Case 1,  
longitudinal,  slightly depressed 
lesions were visualized after 
indigo carmine spraying (D).
Fig. 4　 Endoscopic images of 
CMV involvement in the duode-
num.  Duodenal lesions are seen 
as ulcers (A,  Case 5; B,  Case 
8),  redness (C,  Case 1),  multiple 
erosions,  single erosion,  edema,  
even in the intact mucosa (D,  
Case 6).
infection in the upper gastrointestinal tract who were 
diagnosed at a single institution in Japan during a 
roughly 12-year period revealed CMV involvement in 
the esophagus (n = 3),  stomach (n = 9),  and duodenum 
(n = 6).  In the esophagus,  we observed mucosal alter-
ations such as redness,  erosions,  and ulcers.  Wang et al.  
reported the apparently largest series of patients with 
regard to CMV esophagitis [8].  They found 16 patients 
with histologically proven CMV infection in the esoph-
agus and noted the following endoscopic features:  
multiple ulcers in 14 patients (87.5%),  friable mucosa 
in 10 patients (62.5%),  and polypoid,  nodular surface 
in 1 patient (6.25%).  Another report by Bonetti et al.  
included 9 patients with esophageal CMV lesions,  and 
the authors reported ulcers in 7 (77.8%),  erosions in 
three (33.3%),  and thickened mucosal fold in one 
patient (11.1%) [2].
Representative features of CMV esophagitis have 
been known to be discrete,  superficial ulcers of ovoid,  
elongated,  or diamond-shaped configuration [10 , 11].  
The intervening mucosa between ulcers generally 
appears to be intact and lacks obvious inflammation or 
edema.  In our study,  only Case 14 showed such typical 
morphology (Fig. 2C , D).  The differential diagnoses of 
esophageal discrete ulcers include HIV infection,  her-
pes simplex virus infection,  and drug-induced esopha-
gitis.
In our patient series,  the gastroduodenal lesions 
showed various morphologic types,  redness,  edema,  
erosions,  exfoliated mucosa,  and even visually intact 
mucosa (Figs. 3 , 4).  An earlier report noted that gastro-
duodenal involvement in CMV infection has non-spe-
cific manifestations [2].  Endoscopic features of CMV 
infection in the stomach that have been reported range 
from patchy erythema to thickened mucosa,  hypertro-
phy of the gastric folds,  exudates,  erosions,  and ulcers 
[2 , 12].  The morphologies of reported CMV-related 
duodenal lesions include mucosal depigmentation [13],  
erosion [9],  ulcers with or without fresh bleeding 
[14 , 15],  and pseudotumor formations [16].
It is noteworthy that in our present investigation,  
the numbers of patients with CMV involvement in the 
stomach (9/14,  64.3%) and the duodenum (6/14,  
42.9%) were greater than the number of patients with 
CMV involvement in the esophagus (3/14,  21.4%).  
This finding of a higher prevalence of gastric involve-
ment (19/30,  63.3%) compared to the esophagus (9/30,  
30.0%) was also noted by Bonetti et al.  [2].  Conse-
quently,  we consider that for the precise evaluation of 
the gastroduodenal mucosa to detect CMV infection in 
at-risk patients,  it is essential to perform an endoscopic 
examination and biopsy sampling from gastroduodenal 
lesions with any mucosal alterations or even intact gas-
troduodenal mucosa.
In this study,  all patients had been taking one or 
more immunosuppressive agents such as cyclosporine,  
steroids,  mycophenolic acid,  tacrolimus,  or metho-
trexate.  In addition,  13 of the 14 patients had hemato-
logic diseases and 12 underwent stem cell transplanta-
tion.  Our present findings are in agreement with the 
well-known finding that the reactivation of CMV 
occurs more frequently in immunocompromised 
patients [17 , 18].  Other risk factors for gastrointestinal 
CMV infection are HIV infection,  solid organ trans-
plantation,  malignant diseases,  and chemotherapy.  
Nevertheless,  physicians should keep in mind that 
CMV infection in the gastrointestinal tract also occurs 
in immunocompetent individuals [19].
CMV antigenemia testing is a rapid,  quantifiable 
assay to detect CMV pp65 lower matrix phosphopro-
tein in peripheral blood polymorphonuclear leucocytes 
[20].  Generally,  an antigenemia assay has a lower sen-
sitivity in patients with localized CMV infection than in 
patients with systemic CMV infection.  For example,  
the sensitivity of CMV antigenemia testing for diagnos-
ing CMV viremia is reportedly 93.5% [21],  while it 
ranges from 50% to 54% for gastrointestinal CMV 
involvement [3 , 22].  In the present study,  11 of the 14 
patients (78.6%) were positive for CMV antigenemia 
testing before undergoing EGD.  Of the remaining 3 
patients,  the test was positive in 2 patients at 4 days 
and 11 days after their EGD examination,  respectively.  
In those 3 patients,  CMV was undetectable by CMV 
antigenemia testing before EGD,  probably because the 
CMV viral load within blood was small at that time,  
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Table 3　 Summary of the endoscopic features
Esophagus Stomach Duodenum
Intact 0 0 1
Redness 1 7 2
Edema 0 0 1
Erosion 1 4＊ 3
Ulcer 1 0 2
Exfoliated mucosa 0 2 0
＊One case was presented as verrucous erosions.
despite positive gastrointestinal CMV involvement.  It is 
likely that the changes in the 2 patients’ CMV antigene-
mia testing to positive reflected an increase of the viral 
load within blood after their EGD examinations.
The relatively higher sensitivity (78.6%) for diagnos-
ing gastrointestinal CMV disease shown in our study 
may have been obtained because the subjects of this 
study included 12 patients who underwent stem cell 
transplantation and had periodic CMV antigenemia 
testing.  In addition,  the hematologic diseases and/or 
the immunosuppressive treatments after stem cell 
transplantation might have predisposed the patients to 
CMV viremia.  Finally,  in this study,  the false-negative 
rate of the CMV antigenemia assay before EGD was 
21.4%.  These results indicate that an EGD examination 
is still required to detect a CMV infection in the upper 
gastrointestinal tract,  even in patients with a negative 
CMV antigenemia test result.
Several limitations of this study should be noted.  
First,  not all patients with mucosal alterations in the 
upper gastrointestinal tract underwent biopsy examina-
tions and immunostaining for CMV,  and several 
patients with CMV infection might thus have been 
overlooked.  Second,  GVHD may affect the macro-
scopic appearance of the upper gastrointestinal tract.  It 
was reported that various mucosal changes occur in 
patients with GVHD,  such as redness,  erosions,  ulcers,  
and lusters [23].  The gastric exfoliated mucosa 
observed in Case 4 and Case 10 (Fig. 3B) is one of the 
representative findings of GVHD,  rather than CMV 
infection,  although both of these patients showed no 
evidence of GVHD in a histological evaluation of biop-
sied samples.  Physicians must therefore carefully differ-
entiate CMV infection from GVHD and consider the 
possibility of the concurrence of both diseases.
In conclusion,  we reviewed endoscopic and clinical 
features of 14 patients with CMV infection in the upper 
gastrointestinal tract.  More than 90% of the patients 
had undergone stem cell transplantation.  The CMV 
antigenemia assay before EGD was positive in less than 
80% of the cases,  suggesting that the examination can-
not sufficiently exclude CMV infection in the upper 
gastrointestinal tract.  Macroscopic features were not 
specific or even visually intact.  Physicians must con-
sider CMV infection when any mucosal alterations exist 
in the upper gastrointestinal tract of immunosup-
pressed patients.
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